First Time Loading...

Wuhan Easy Diagnosis Biomedicine Co Ltd
SZSE:002932

Watchlist Manager
Wuhan Easy Diagnosis Biomedicine Co Ltd Logo
Wuhan Easy Diagnosis Biomedicine Co Ltd
SZSE:002932
Watchlist
Price: 20.79 CNY 1.81% Market Closed
Updated: May 3, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

3.7B
-37%
Revenue
Growth Rates:
1 Year
-56%
3 Years
+441%
5 Years
+1 945%
7 Years
-
10 Years
-
613.5m
-68%
Operating Income
Growth Rates:
1 Year
-88%
3 Years
+46%
5 Years
+687%
7 Years
-
10 Years
-
515.3m
-67%
Net Income
Growth Rates:
1 Year
-88%
3 Years
+46%
5 Years
+670%
7 Years
-
10 Years
-

Earnings Waterfall
Wuhan Easy Diagnosis Biomedicine Co Ltd

Revenue
3.7B CNY
Cost of Revenue
-2B CNY
Gross Profit
1.6B CNY
Operating Expenses
-1B CNY
Operating Income
613.5m CNY
Other Expenses
-98.2m CNY
Net Income
515.3m CNY

Income Statement
Wuhan Easy Diagnosis Biomedicine Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023
Revenue
Revenue
179
N/A
180
+1%
176
-2%
186
+5%
180
-3%
184
+2%
181
-1%
163
-10%
440
+170%
682
+55%
959
+41%
1 608
+68%
1 740
+8%
2 257
+30%
2 830
+25%
4 640
+64%
6 942
+50%
8 361
+20%
10 530
+26%
8 415
-20%
5 815
-31%
3 686
-37%
Gross Profit
Cost of Revenue
(38)
(39)
(40)
(43)
(42)
(45)
(47)
(46)
(86)
(136)
(209)
(367)
(430)
(566)
(707)
(1 220)
(2 093)
(2 587)
(3 991)
(3 600)
(2 684)
(2 037)
Gross Profit
141
N/A
141
0%
136
-4%
143
+5%
138
-3%
139
+0%
135
-3%
117
-13%
354
+204%
545
+54%
750
+38%
1 240
+65%
1 310
+6%
1 692
+29%
2 123
+25%
3 421
+61%
4 849
+42%
5 775
+19%
6 540
+13%
4 816
-26%
3 130
-35%
1 649
-47%
Operating Income
Operating Expenses
(61)
(63)
(72)
(78)
(81)
(88)
(101)
(97)
(116)
(126)
(192)
(247)
(295)
(347)
(432)
(455)
(527)
(636)
(1 393)
(1 436)
(1 207)
(1 036)
Selling, General & Administrative
(44)
(48)
(52)
(56)
(57)
(59)
(65)
(65)
(79)
(94)
(134)
(175)
(208)
(234)
(303)
(346)
(401)
(442)
(1 012)
(927)
(830)
(762)
Research & Development
(23)
(24)
(27)
(30)
(34)
(36)
(37)
(36)
(40)
(47)
(70)
(86)
(100)
(114)
(133)
(139)
(140)
(209)
(388)
(393)
(403)
(340)
Depreciation & Amortization
(1)
0
(1)
0
0
0
(2)
0
0
0
(2)
0
0
0
(5)
0
0
0
(11)
0
0
0
Other Operating Expenses
7
10
8
8
9
6
3
3
3
15
14
14
13
1
8
30
15
15
18
(116)
26
66
Operating Income
80
N/A
78
-3%
64
-18%
65
+2%
57
-13%
50
-11%
34
-33%
20
-42%
238
+1 115%
419
+76%
558
+33%
993
+78%
1 016
+2%
1 344
+32%
1 691
+26%
2 966
+75%
4 322
+46%
5 139
+19%
5 147
+0%
3 380
-34%
1 924
-43%
614
-68%
Pre-Tax Income
Interest Income Expense
2
2
4
6
8
10
8
8
4
4
4
2
5
7
7
12
34
46
74
100
108
122
Non-Reccuring Items
0
(0)
0
(1)
(1)
(1)
0
0
1
1
0
(21)
0
0
0
0
0
0
(141)
0
(141)
(141)
Total Other Income
(1)
(4)
3
3
8
8
5
2
(6)
(6)
(6)
(2)
(0)
(3)
(3)
(3)
(5)
(2)
(4)
(5)
(6)
(6)
Pre-Tax Income
81
N/A
76
-7%
71
-7%
73
+4%
72
-2%
67
-6%
47
-31%
30
-36%
238
+695%
419
+76%
557
+33%
972
+75%
1 020
+5%
1 349
+32%
1 695
+26%
2 974
+76%
4 351
+46%
5 182
+19%
5 076
-2%
3 476
-32%
1 885
-46%
588
-69%
Net Income
Tax Provision
(11)
(8)
(8)
(8)
(7)
(7)
(4)
(2)
(35)
(61)
(81)
(148)
(152)
(199)
(248)
(448)
(664)
(784)
(696)
(443)
(198)
(11)
Income from Continuing Operations
71
68
63
65
64
60
43
28
203
357
476
823
869
1 150
1 447
2 526
3 687
4 398
4 380
3 032
1 687
577
Income to Minority Interest
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(7)
(15)
(21)
(32)
(33)
(65)
(93)
(152)
(172)
(138)
(127)
(61)
Net Income (Common)
70
N/A
67
-5%
61
-8%
64
+4%
63
-1%
58
-8%
42
-29%
27
-34%
201
+637%
353
+75%
469
+33%
808
+72%
848
+5%
1 118
+32%
1 413
+26%
2 461
+74%
3 594
+46%
4 246
+18%
4 208
-1%
2 895
-31%
1 561
-46%
515
-67%
EPS (Diluted)
1.4
N/A
1.08
-23%
1.08
N/A
0.95
-12%
0.95
N/A
0.87
-8%
0.62
-29%
0.41
-34%
3.03
+639%
5.3
+75%
6.98
+32%
11.73
+68%
6.1
-48%
7.56
+24%
6.68
-12%
16.27
+144%
22.51
+38%
18.34
-19%
18.31
0%
12.59
-31%
6.74
-46%
2.21
-67%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.